Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid is an experimental small molecule belonging to the class of biphenyl derivatives. It features a chiral center at the 2-position and contains both biphenylyl ether and phenyl groups attached to a propanoic acid backbone. The compound has been studied for its interaction with nuclear hormone receptors, particularly as a ligand for peroxisome proliferator–activated receptor gamma (PPAR-gamma), which plays roles in glucose metabolism and adipogenesis. Its precise mechanism of action and therapeutic applications remain under investigation; it is not approved for clinical use[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid.